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Summary 
Loss ofT cell-associated signal transduction molecules has recently been implicated in immune 
suppression  in tumor-beating  hosts.  In the  present study,  we have  examined  this  and related 
phenomenon  extensively  in  a  large  number  of tumor-beating  mice,  analyzed  individually. 
Splenic  T  cells from tumor-beating  mice were  isolated and characterized  with respect to the 
following:  (a)  levels  of three  tyrosine  kinases,  p56  tck, p59~",  and  ZAP-70;  (b)  expression  of 
CD3-~; (c) alloreactive responses; and (d) antigen-specific responses. Contrary to recent reports, 
T  cells from tumor-bearing mice were observed to express normal levels of lck, fyn,  ZAP-70, 
and CD3-~. Further, T  cells showed healthy alloreactive and antigen-specific responses until ~3 
wk after post tumor challenge, when the tumors constituted -20% of the body weight.  Alter- 
ations with respect to some parameters were observed only in mice that had been beating larger 
tumors for a considerably longer period.  As human tumors are unlikely to grow to such large 
sizes (e.g.,  >20% of the total body weight),  the significance of the alterations in T  cell expres- 
sion of Ick, fyn,  ZAP-70,  or CD3-r  in the  immune status of cancer patients  is unclear.  Alto- 
gether,  these results indicate  that alterations in T  cell signal transduction  molecules do not ac- 
count for the profound tumor-specific suppression observed during tumor growth. 
T 
he escape of immunogenic tumors from host immune 
response  has long  defined  the  central  paradox  of tu- 
mor immunology,  and many mechanisms by which  a pri- 
mary tumor  evades  destruction  have  been  suggested  (1--4). 
Most  recently,  efforts  to  explain  immunological  suppres- 
sion  during  tumor  growth  have  focused  on  the  apparent 
molecular  defects in T  cells in  tumor-beating  hosts  (5-9). 
These  studies  have suggested  that  down-regulation  of the 
tyrosine kinases, p56 lck, p59fY", ZAP-70,  and the ~ chain as- 
sociated  with  both  CD3  and  CD16,  could  contribute  to 
impaired function of T  cells and NK cells isolated from tu- 
mor-beating mice and patients. 
To develop a broad understanding  of the immunological 
alterations  during progressive tumor growth,  we have  ex- 
amined individual  mice for the following:  (a) levels of ex- 
pression of p56/'k, p59-~", ZAP-70,  and CD3-~;  (b) the abil- 
ity to generate an alloreactive response; and (c) the ability to 
generate an antigen-specific  response in T  cells from naive 
and tumor-bearing mice. We have done so in four different 
chemically  and  UV-induced  tumors  of two  haplotypes. 
Our  results  indicate  that  the  known  alterations  in  T  cell 
structure and function during progressive tumor growth are 
quite  subtle  except  at  the  very  end  stages  of disease,  and 
they do not account for the  profound tumor-specific  sup- 
pression seen during tumor growth. 
Materials and Methods 
Animals and Tumor Cells.  BALB/cJ and C57B1/6  mice were 
obtained from The Jackson Laboratory (Bar Harbor, ME),  and 
C3H-HeN mice were from Harlan Sprague Dawley, Inc. (India- 
napolis,  IN). Meth A, CMS4,  CMS5,  UV-6139  (10),  rat baso- 
philic leukemia (RBL)  (gift of Richard Klausner),  CT-26, B/c- 
N, and B/c-NP were maintained in vitro in DMEM with sup- 
plements as described (11). 
Tumor Challenges and Immunization.  Mice  were  challenged 
and immunized according to Srivastava et al. (I I). 
Mixed Lymphocyte  Reactions (MLRs), i Mixed Lymphocyte  Tumor 
Cultures (MLTC), and Cytotoxicity  Assays.  MLILs, MLTCs,  and 
S~Cr release assays were carried out as described. (12). 
Purification of T  Cells and FACS  ~ Analysis.  T  cells were posi- 
tively  selected  from  splenocytes  using  magnetic  bead-coupled 
anti-Thyl.2 antibody and a cell sorting system (MACS, Miltenyi 
Biotec Inc., Sunnyvale, CA). Purity of enriched T  cells (>95%) 
was  assessed  by  FACScan  |  (Becton  Dickinson  &  Co.,  Cock- 
eysville,  MD), using ctCD3e antibody (clone 145-2Cll;  Pharm- 
ingen, San Diego, CA). 
Immunoblotting  and Immunoprecipitation.  Lysates  of T  cells  or 
R_BL tumor cells  were  blotted  and  immunoprecipitated  as  de- 
scribed  (11).  Blots were  probed  with  antiserum to  Ick and fyn, 
1Abbreviations used in  this paper: MLtL, mixed  lymphocyte  reaction; 
MLTC, mixed lymphocyte tumor culture; tLBL, rat basophilic leukemia. 
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Lake Placid, NY), or antiserum to CD3-~ (a kind gift of Dr. Ri- 
chard P,  obb,  Oncotherapeutics,  Inc., Cranbury,  NJ)  and devel- 
oped with peroxidase-conjugated antibody to rabbit by enhanced 
chemiluminescence  (Amersham  Corp., Arlington Heights,  IL). 
Results 
A  number of  independent immunological parameters re- 
lating to T  cell structure and function were monitored dur- 
ing progressive tumor growth. Splenic T  cells from tumor- 
bearing mice were isolated and analyzed for the following: 
(a)  levels  of expression  of three  tyrosine  kinases,  Ick, fyn, 
and ZAP-70;  (b)  expression of CD3-associated ~ chain;  (c) 
alloreactive  responses;  and  (d)  antigen-specific  T  cells  re- 
sponses. 
Expression of Signal Transduction Molecules, lck, fyn,  ZAP- 
70,  and  CD3-associated ~  in  T  Cells during Tumor Growth. 
BALB/cJ (H-2  d)  mice  were  challenged  intradermally  with 
antigenically distinct methylcholanthrene-induced fibrosar- 
comas,  Meth  A,  CMS4,  or CMS5.  All tumors grow pro- 
gressively and kill their hosts between 6 and 12 wk after tu- 
mor challenge,  depending on the tumor.  Mice were killed 
periodically,  and splenic  T  cells  were enriched by positive 
selection  using  magnetically  coupled  cxThyl.2  antibody 
and  the  MACS  cell  sorting  system.  T  cells  were  consis- 
tently >95% pure, as analyzed by FACScan  |  using {xCD3~ 
antibody.  Splenic  T  cells  from naive  mice  were  similarly 
isolated and used as controls in each experiment.  T  cell ly- 
sates  applied to SDS-PAGE, transferred to polyvinylditluo- 
ride  membrane,  and probed with  antisera  to  each  of four 
signal transduction molecules, lck,  fyn, Zap-70, and CD3-{. 
In total, ~100 mice were examined individually. 
Ick is  observed  to be present  in  splenic  T  cells  of naive 
mice  and  in  nearly  all  tumor-bearing  mice.  Only  at  the 
most  extreme  stages  of tumor  growth  (day 45)  is  Ick ob- 
served  to  be  absent  in  CMS5-bearing  mice  (Fig.  1).  This 
loss is similarly seen  in  CMS4  and Meth  A  bearers  at  this 
stage  (data  not  shown).  T  cells  were  similarly  isolated  by 
positive selection from two  C3H-HeN  (H-2  k)  mice bear- 
ing large UV-6139 tumors  (day 55).  lck is substantially de- 
creased  in  the  first mouse and is  missing in  the  second,  as 
compared with a naive control (Fig.  1).  These studies have 
been  carried  out in  >50  mice  individually.  They indicate 
that lck expression in T  cells  ill tumor bearing varies mod- 
erately from mouse to mouse,  and that significant loss oc- 
curs only during the very late  stages of the  tumor-bearing 
period. 
fyn  is  observed  to be  present  in BALB/cJ  mice  bearing 
10- and 45-d tumors at levels comparable to control non- 
tumor-bearing  mice  (Fig.  2).  In  additional  experiments 
with these tumors, fyn was analyzed at 8, 16, 26, 30, 35 and 
45 d  after tumor challenge,  and it is observed to be present 
in all T  cells  isolated  (data not shown).  In contrast to these 
results with BALB/cJ mice, fyn was observed to be absent 
in T  cells  isolated from two late-stage  (day 55)  UV 6139- 
bearing C3H-HeN mice (Fig. 2). 
The  recent  discovery of a  novel  tyrosine  kinase,  ZAP- 
70,  has added another level of complexity to TCR  signal- 
ing (13,  14). While a defect in ZAP-70 has been implicated 
in human severe combined immunodeficiency (15)  and in 
selective  T  cell  deficiency  (16),  no  previous  reports  have 
documented  the  effects  of tumor  burden  on  this  tyrosine 
kinase.  Splenic  T  cells  were  isolated  by positive  selection 
from Meth A and UV 6139 tumor-beating mice. In Meth A 
bearers,  T  lymphocytes from mice bearing 10-d-old tumors 
show  ZAP-70  levels  comparable  with  those  of control 
mice.  Mice  beating  34-  or  45-d-old  tumors,  however, 
Figure 1.  Expression  of  p56  t'~ in splenic T cells 
isolated from tumor-bearing mice. T  cells were 
isolated by positive selection from CMS4, CMS5, 
Meth A, and UV 6139 tumor bearers (see Materi- 
als and Methods). T cell purity was >95%. Cell 
extracts were subjected to SDS-PAGE were im- 
munoblotted, and were probed with antiserum to 
the COOH or NH2 terminus oflck. Day 0 repre- 
sents T  cells isolated from naive mouse spleno- 
cytes. 
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bearing mice. For experimental details,  see the legend to Fig.  1 and the 
Materials and Methods section. All immunoblots were probed with anti- 
serum tofyn synthetic peptide. RA3L is a negative control forfyn. 
show a significant decrease in ZAP-70 expression. In mice 
bearing UV 6139 (day 55), ZAP-70 is observed to be com- 
pletely absent (Fig. 3). 
CD3-~  has  been  the  subject  of extensive reports  con- 
cerning T  cell development in the thymus and T  cell func- 
tion in the periphery (17-21), thus generating particular in- 
terest regarding its  role  in  T  cell  abnormalities  in  tumor 
bearers. Similar to analysis of lck, fyn,  and ZAP-70, expres- 
sion of CD3-~ was examined at all stages of tumor growth, 
with  emphasis  on  late  tumor  bearers.  For  initial  experi- 
ments, the total T  cell lysates were subjected to 14% SDS- 
PAGE, immunoblotted, and probed with anti-~ antiserum 
(Fig. 4 A). ~ was observed to be present in all lysates exam- 
ined, including late CMS4 and Meth A tumor bearers (day 
34).  In  two  exceptional cases  (2 out of 10),  mice bearing 
early CMS4  and  Meth  A  tumors  (day  10)  showed a  de- 
crease in ~ expression. Additional experiments focused on 
later stages  of Meth A  tumor growth, and ~ was observed 
to be present even in mice bearing 45-d tumors (data  not 
shown). 
These experiments did not address  the possibility that ~, 
although present, might dissociate from the CD3 complex, 
thus disrupting the cascade of signaling events. To address 
this  possibility in  Meth  A  and  CMS5  tumor bearers,  the 
CD3  complex was precipitated with ctCD3e  (clone  145- 
2Cll), subjected to 14% SDS-PAGE, immunoblotted, and 
probed with anti-~ antiserum (Fig.  4  B). Again,  ~ was de- 
tected in  all nonprecipitated lysates  at  all stages  of tumor 
growth.  In precipitated lysates,  ~ is similarly detectable in 
Meth A  tumor bearers through day 29,  and in CMS5  tu- 
mor bearers  through  day  53.  In  very late-stage  Meth  A 
bearers (day 34), ~ is not detectable after precipitation, sug- 
gesting dissociation from the CD3 complex. Similar to the 
analysis  of lck,  expression of CD3-~  was  extensively ana- 
lyzed in highly enriched T  cells  isolated from >50  mice. 
Altogether, these results  demonstrate that,  in nearly every 
mouse examined, ~ is not only present but remains associ- 
ated with the CD3 complex. The cases where ~ is present 
but has  dissociated from other CD3  components are  ob- 
served only in T  cells isolated from some mice with greatly 
advanced disease. 
Figs.  1--4 show representative examples of expression of 
the various signal  transduction-related molecules in T  cells 
from tumor-bearing mice. However, these examples repre- 
sent  only  a  proportion  of the  mice  examined.  Table  1 
shows the compiled results  of analyses  of expression of lck, 
fyn,  and  CD3-~  in  T  cells  from  mice  bearing  Meth  A, 
CMS4,  CMSS,  or  UV-6139  at  various  stages  of tumor 
growth. The results from all mice whose T  cells were ex- 
amined for expression of  at least two of  the three molecules 
are included in this table.  It is obvious from this compre- 
hensive and extensive compilation that, in general, T  cells 
from mice bearing large tumors are competent with respect 
Figure 3.  Expression of ZAP-70 tyrosine kinase in splenic T  cells iso- 
lated from tumor-bearing mice. T  cell lysates were prepared as described 
(Fig.  1 and Materials and Methods) and immunoblots probed with poly- 
clonal antibody to ZAP-70. RBL is a negative control for ZAP-70. 
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Figure 4.  Expression of CD3-~ in splenic T  cells isolated from BALB/ 
cJ tumor-bearing mice. Whole cellular extracts (A) or extracts first pre- 
cipitated with monoclonal otCD3~ (B) were apphed to SDS-PAGE, im- 
munoblotted, and probed with ~x/~ antiserum.  N  indicates nonprecipi- 
tated lysates,  while  P  indicates precipitated lysates.  RBL  is  a  negative 
control for ~. Table  1.  Comparison  of Expression of Signal Transduction Molecules in T Cells  fiom Mice Bearing Meth A, CMS4, CMS5, 
or UV6139 Tumors 
Presence of.'** 
Days of tumor  Average tumor 
Tumor  burden  diameter*  lck  fyn  CD3-{  Tumor 
Days of tumor  Average tumor 
burden  diameter 
Presence of: 
lck  fyn  CD3-~ 
mm  mm 
Meth A  0  0  +  + +  + + +  CMS4  0  0 
0  ++  +  +++  8 
0  ++  ++  nd  10  6.1 
0  ++  ++  nd  10 
8  ++  ++  nd  10 
10  6.0  +  +  -  16 
10  ++  +  +  18  8.0 
10  ++  ++  nd  18 
18  15.5  ++  ++  +++  26  ll.0 
18  ++  ++  +++  26 
25  26.0  +++  +  +++  26 
25  ++  ++  +++  30 
25  ++  +  ++  34 
26  ++  ++  +++  34 
26  ++  ++  ++  35 
26  + +  +  +  nd  45 
28  ++  +  +++ 
28  + +  + +  + + +  CMS5  0  0 
28  +++  +++  +++  8  5.0 
30  + +  + +  nd  26  14.0 
32  27.3  +  +  +  +  +  + +  30 
32  +  ++  +++  35 
32  +  ++  +++  45 
32  +  ++  +++ 
34  ++  ++  +++  UV6139 
34  +++  ++  +++ 
35  -  + +  nd 
45  -  ++  nd 
+  ++  +++ 
++  ++  nd 
+  +  -- 
++  +  + 
++  ++  nd 
+  ++  nd 
++  +  +++ 
++  +  +++ 
++  ++  +++ 
++  ++  ++ 
+  ++  nd 
+  ++  nd 
++  ++  +++ 
+++  ++  +++ 
-  ++  nd 
-  ++  nd 
+  ++  +++ 
++  ++  nd 
++  ++  nd 
++  ++  nd 
+ +  ++  nd 
-  ++  nd 
0  0  + +  +  nd 
55  25.0  +  -  nd 
55  -  -  nd 
* Shown are representative tumor diameters. 
** + +  represents average expression, as detected by immunoblotting with specific  antibody, as shown in Figs. 1-4,  + + +,  two  or more times 
higher than average expression; +, 50% or lower than average expression, -, no expression, nd, not determined. 
to  expression of the signal transduction-related  molecules. 
Among  mice bearing tumors for 25 d  or longer, relative or 
absolute loss oflck was observed only in 2  out  of 18  mice 
bearing Meth A, two out of eight mice bearing CMS4,  one 
out of four mice bearing CMSS,  and one out of two  mice 
beating UV6139.  Relative or absolute loss offyn was never 
observed in mice  bearing Meth  A,  CMS4,  or CMS5,  but 
was  detected  in  two  mice  bearing  55-d-old  UV6139  tu- 
mors.  Relative  or  absolute  loss  of CD3-~  was  never  ob- 
served in mice bearing large tumors.  These results demon- 
strate  that  the  overwhelming  majority  of mice  contain  a 
normal  complement  of signal  transduction  molecules  and 
that losses  are  very  infrequent,  even  at  advanced  stages  of 
tumor growth. 
Loss of Alloreactiuity During Tumor Growth.  In  addition 
to  monitoring  structural  parameters  (see  Fig.  1-4),  two 
functional  properties  of T  cells  from  tumor-bearing  mice 
were  tested  as  a  function  of tumor  growth,  including  al- 
loreactive  and  antigen-specific  responses.  Three  separate 
groups  of  BALB/cJ  mice  were  challenged  intradermally 
with  CMS4,  CMS5,  or Meth  A  tumor  cells.  To  assess  al- 
loreactivity,  MLRs  were  established.  Beginning  9  d  after 
tumor  challenge  and at  10-14-d  intervals  thereafter,  sple- 
nocytes from tumor  bearers were  divided  equally  and cul- 
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Figure 5.  Loss ofalloreactivity during tumor growth. Splenocytes from BALB/cJ tumor-bearing mice were prepared for MLRs as described. Mitomy- 
cin C-treated splenocytes from naive C57B1/6 and C3H/HeN mice served as stimulator cells.  CTL assays were performed on day 5 with SlCr-labeled 
target cells consisting of Con A~stimulated naive C57B1/6 (A) or C3H-HeN (/3) spleen cells.  The number of days after tumor challenge when MLP,  s 
were established is indicated at the top left of each figure. Meth A tumor-bearing mice were not analyzed on day 38 or 52. (--O--), naive; (--O-), CMS4; 
(--[~), CMS5; and (--m--), Meth A. 
tured  with  either  mitomycin  C-inactivated  C57B1/6  or 
C3H-HeN  stimulator  cells.  On  day  5,  CTL  assays were 
performed as described in Materials and Methods, with tar- 
get cells  consisting of Con A-stimulated C57B1/6  (Fig.  5 
A) or C3H-HeN (Fig.  5 B) splenocytes. 
Splenocytes  from  mice  bearing  tumors  up  to  ~3  wk 
showed  normal  levels  of alloreactivity  to  C57B1/6  and 
C3H-HeN stimulators in 51Cr release assays (Fig.  5, A  and 
B). In contrast, MLR.s that included responding splenocytes 
from large Meth A  tumor bearers (>3 wk) showed a 50% 
or greater loss of alloreactivity. This loss begins 19  d  after 
tumor challenge in response to C3H-HeN stimulators, and 
on day 28 in response to C57B1/6  stimulators.  CMS4 and 
CMS5 tumor-bearing mice show a less dramatic loss of al- 
loreactivity  in  these  studies.  By  day  52,  the  response  of 
these splenocytes to C57B1/6 stimulators is reduced by 30% 
(Fig.  5 A), with only a slightly reduced response to C3H- 
HeN stimulators (Fig.  5 B). The modest loss of alloreactiv- 
ity  in  CMS4  and  CMS5  tumor  bearers  compared  with 
Meth A tumor bearers correlates with slower growth kinet- 
ics of CMS4 and CMS5  tumors. In other experiments in- 
volving  mice  bearing  larger  CMS4  and  CMS5  tumors, 
however,  a  loss  of alloreactivity  comparable  to  Meth  A 
bearers is observed (data not shown). 
To  evaluate the  antigen-presenting function  of spleno- 
cytes isolated from tumor bearers, the responder and stimu- 
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lator cells in MLRs were reversed. Splenocytes from mice 
with either small (day 8) or very large tumors (day 30) were 
treated with  mitomycin C  and  used  as stimulators,  while 
splenocytes from naive mice served as responders. CTL as- 
says revealed normal levels of cytotoxicity, suggesting that 
antigen-presenting function in splenocytes of tumor bearers 
is intact (not shown). 
Loss of Antigen-specific T  Cell Responsiveness During Tumor 
Growth.  Loss of alloreactivity is observed only in late tu- 
mor-bearing  mice  (see  Fig.  5),  suggesting  that,  in  mice 
bearing smaller tumors, T  cell-mediated immunity is spe- 
cifically suppressed with respect to the tumor implant, but 
not with respect to other antigens. This was tested by im- 
munizing Meth A-bearing mice with the highly immuno- 
genic BALB/c colon carcinoma line, CT-26, and assessing 
the  ability of mice to  generate  a  tumor-specific CTL re- 
sponse to CT-26 tumor.  Two groups of mice were chal- 
lenged intradermally with  1  ￿  105 Meth A  cells staggered 
at a  14-d interval (Fig.  6, bottom). Mice received their first 
immunization with irradiated CT-26 cells either 6 d or 20 d 
after tumor challenge,  and  their second immunization  13 
or 27  d  after tumor challenge.  Non-tumor-bearing  mice 
were similarly immunized. 3 d after the last immunization, 
mice were killed and splenocytes were cultured with irradi- 
ated CT-26 stimulators at a ratio of 200:1. On day 6, CTLs 
were  tested  in  a  chromium  release  assay against  CT-26, {o 
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Figure 6.  Suppression of tumor-specific reactivity to  CT-26  tumor 
cells in mice bearing large Moth A tumors. Naive mice were immunized 
twice at weekly intervals with whole irradiated CT-26 cells, and MLTCs 
were established as described. On day 6, CTLs were tested against SlCr- 
labeled CT-26, B/c-N, and B/c-NP targets, as indicated (A). Meth A tu- 
mor-beating  mice were  similarly immunized with CT-26  cells. The 
number of days after tumor challenge when MLTCs were established is 
indicated (B). The SICr-labeled target cell is CT-26. The time course of 
tumor challenges and immunizations is indicated for each group of mice 
at the bottom of  the figure. 
B/c-NP  (BALB/c fibroblast transfected with the NP gene 
of PR8  influenza  virus),  and  B/c-N  (parental,  nontrans- 
fected fibroblast line)  target cells.  CTLs derived from non- 
tumor-bearing  mice  that  were  immunized  with  CT-26 
show vigorous cytotytic activity against CT-26 target cells, 
but not against B/c-N or B/c-NP targets (Fig. 6 A). Sple- 
nocytes  from  mice  bearing  17-d  tumors  at  the  time  of 
MLTC  also  generate  a  vigorous CTL response  to  CT-26 
(Fig.  6  B).  This  response  is  even greater  than  CTLs from 
the  control non-tumor-bearing mice.  In contrast,  spleno- 
cytes from mice bearing 30-d tumors at the time of MLTC 
generate a negligible  T  cell response  to CT-26.  This  sug- 
gests that T  cells  in mice bearing tumors up to ~3  wk are 
capable not only of responding broadly to atloantigens but 
are also capable of responding specifically to a syngeneic tu- 
mor antigen.  However,  both  of these  responses  are  soon 
lost in mice bearing tumors longer than 3 wk. 
Discussion 
There has been considerable interest recently in the ob- 
served loss of signal transduction molecules from T  cells  of 
tumor-beating hosts, as reported in two routine tumor sys- 
tems  (5,  8,  9),  and subsequently in human cancer patients 
(6,  7).  Our results  (Figs.  1-4  and  Table  1)  are  apparently 
dissonant  with  these  findings.  First,  it  was  observed  that 
splenic T lymphocytes derived from the majority of BALB/cJ 
mice bearing CMS4,  CMS5, or Meth A  tumors, and from 
C3H-HeN mice beating UV 6139 tumors, contained nor- 
mal levels of the Wrosine kinases Ick and ZAP-70, although 
some mice with greatly advanced tumors show a decrease 
or complete loss of expression. Second, it was observed that 
the tyrosine kinasefyn is present at normal levels in T  cells 
isolated from all BALB/cJ tumor-bearing mice and is miss- 
ing from T  cells  isolated  from C3H/HeN  tumor-bearing 
mice.  Third,  normal levels  of CD3-~  were  detected  in  T 
cells isolated from all BALB/cJ tumor-bearing mice, although 
dissociation  of ~ from the  CD3  complex was  observed  at 
very late stages of tumor growth. We have examined T  cells 
for their  content  of signal  transduction  molecules  in  four 
antigenically distinct tumor systems, comprising two haplo- 
types. These studies were done at various time points and 
involved >100 mice, individually examined.  In total, these 
results  suggest  that  the  alterations  in  signaling  molecules 
may not be prevalent with equal severity in all  tumor sys- 
tems and that a wide variety of mechanisms could contrib- 
ute  to the  down-regulation  of T  cell-mediated  immunity 
in tumor bearers￿9 
We have considered the variation in experimental design 
that may have led to the significant differences between our 
results  (presented here)  and those in two earlier studies  (5, 
8).  Experiments  in  the  earlier  reports  appear  to  have  in- 
volved pooling T  cells from many mice,  and  they do not 
address  variation  in  expression  from host  to  host,  as  de- 
tected by us (see  Figs.  1 and 4).  Further,  the earlier studies 
presented  results  only from naive  and  late  tumor bearers, 
with only one mention  of analysis of T  cells at other time 
points (8).  In contrast, our study involved inoculating large 
groups  of mice  with  tumor  cells,  followed  by analysis  of 
signaling molecules  on an individual  mouse basis  at many 
stages of tumor growth.  It is possible that some of the ob- 
served  defects  in  such  molecules  in  tumor bearers  (5,  8) 
could be attributed to normal fluctuation from host to host. 
For example, in our experiments in which T  cells were iso- 
lated from individual  mice bearing CMS4  or Meth  A  tu- 
mors for the  same  duration  (i.e.,  days  10,  18,  25,  26,  28, 
32, and 34),  considerable variation in expression of Ick was 
1034  Immunological Parameters in Tumor-bearing Mice in fact observed  (Fig.  1).  Interestingly,  a  recent report  (9) 
showed no loss of CD3-~  among the  T  lymphocytes de- 
rived from lymph nodes and intraepithelial  lymphocytes of 
a  late  tumor-bearing  mouse,  although  such  loss  was  ob- 
served in splenic  T  lymphocytes. This  observation under- 
scores  the  fact that any alterations  in TCK  structure  may 
not  be  systemic  but  may  result  from  a  specific  host  mi- 
croenvironment created by some tumors but not others. 
Numerous reports have demonstrated that loss of certain 
signal transduction proteins has deleterious effects on T  cell 
function (16,  17, 22, 23).  CD3-~ chain was reported to be 
replaced by the  Fcey chain  in a  recent study of splenic  T 
cells isolated from C57Bt/6 mice bearing the MCA-38 co- 
lon carcinoma (5).  The functional consequence of this sub- 
stitution  is  not  entirely  clear,  as  normal  lytic  function  of 
such cells in response to antigen stimulation has been dem- 
onstrated (24). 
Normal  alloreactive  T  cell  responses  were  observed  in 
BALB/cJ  mice  bearing  tumors  up  to  ~-,3 wk,  although 
mice bearing tumors for longer periods demonstrate a de- 
crease in alloreactivity.  This loss has been observed in late 
tumor-bearing mice in two other systems (25,  26).  It was 
also  observed  that  mice  bearing  tumors  at  relatively  ad- 
vanced stages of growth (day 17) are capable ofeliciting an- 
tigen-specific T  cell responses  to an unrelated  tumor,  and 
that only in mice bearing tumors 3-4 wk is this ability lost 
(Fig.  6).  This  phenomenon  represents  a  paradox  of im- 
mune suppression,  in that the ability to generate a specific 
T  cell response to another distinct tumor antigen is concur- 
rent with the progressive growth of a highly immunogenic 
tumor in syngeneic hosts.  This suggests that mice are spe- 
cifically suppressed  only with  regard  to the  implanted  tu- 
mor,  and  not with  regard  to  other  antigens.  At very late 
stages of tumor growth, however, a shift from antigen-spe- 
cific to generalized suppression  occurs, such that mice are 
more severely immunocompromised. 
Although  this  study  examined  a  number  of parameters 
associated  with  T  cell  structure  and  function  in  tumor- 
bearing  hosts,  it  has  not  addressed  the  mechanisms  by 
which tumor-specifc suppression  is manifested.  Studies  of 
R.J. North and I. Bursuker have shown that, as early as 9 d 
after tumor challenge, a suppressor T  cell population prolif- 
erates,  reaching maximum  activity by day  16  (1,  2).  Pre- 
sumably,  these  suppressor T  cells  are fully functional with 
respect to the signaling molecules addressed in our study, in 
addition  to retaining the  ability to respond to alloantigens 
and  other  specific tumor antigens.  The  generation  of this 
suppressor  T  cell population  at very early stages  of tumor 
growth is significant in that it suggests that alterations in the 
host immune response do in fact occur very soon after tu- 
mor  transplantation;  however,  these  alterations  are  most 
likely distinct from those alterations at later stages of tumor 
growth, observed in this study. 
To the best of our knowledge, this is the first report that 
examines the immune response to tumor progression in in- 
dividual  mice,  using multiple  parameters,  studied  simulta- 
neously in more than one tumor.  In light of the observed 
maintenance  of immunocompetence  for  the  majority  of 
the life span of tumor-bearing mice, it may prove fruitful to 
further study antigen-specific suppression  at early stages of 
tumor growth, where the chances of permanently eradicat- 
ing tumors greatly increase. 
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Note added in proof" In a forthcoming study of four murine tumor systems (Franco, J., P. Gosh, R. Wiltrout, 
C. Carter, A. Zea, N. Momozaki, A. Ochoa, D. Longo, T. Sayers, and K. Komschlies. 1995. Cancer  Res. In 
press), the authors show that granulocytes contaminating T  cell preparations induce loss of T  cell signaling 
molecules p56  l'k and CD3~, Although the authors do not provide data, they claim that this artifact does not 
account for loss of CD3~ in human cancer  patients.  Another study  (Wang,  Q., J.  Stanley, S. Kudoh, J. 
Myles, V. Kolenko, T. Yi, R. Tubbs, R. Bukowski,  andJ. Finke.  1995.J. Immunol. 155:1382-1392)  shows 
lck  n  a lack of  loss of  p56  , p59~, ZAP-70, and CD3~ in tumor-infiltrating  lymphocytes of  29 patients with non- 
Hodgkin's B cell lymphomas. 
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